BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27088206)

  • 1. [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
    Pawlak-Buś K; Gaca-Wysocka M; Grzybowski A; Leszczyński P
    Pol Merkur Lekarski; 2016 Mar; 40(237):202-6. PubMed ID: 27088206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antimalarial's retinopaty remains a current threat].
    Chiffoleau A; Guillet A; Zanlonghi X; Jolliet P
    Presse Med; 2009 Apr; 38(4):662-3. PubMed ID: 19135848
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
    Aylward JM
    J Am Optom Assoc; 1993 Nov; 64(11):787-97. PubMed ID: 8120333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
    Trefond L; Lhote R; Mathian A; de Chambrun MP; Pha M; Hie M; Miyara M; Papo M; Moyon Q; Taieb D; Saade S; Salem TB; Haroche J; Chasset F; Aubart FC; Zahr N; Amoura Z
    Semin Arthritis Rheum; 2024 Jun; 66():152417. PubMed ID: 38394986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
    Spinelli FR; Moscarelli E; Ceccarelli F; Miranda F; Perricone C; Truglia S; Garufi C; Massaro L; Morello F; Alessandri C; Valesini G; Conti F
    Lupus; 2018 Sep; 27(10):1616-1623. PubMed ID: 29954281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
    Costedoat-Chalumeau N; Dunogué B; Leroux G; Morel N; Jallouli M; Le Guern V; Piette JC; Brézin AP; Melles RB; Marmor MF
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):317-26. PubMed ID: 25672591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimalarial therapy in SLE.
    Lanham JG; Hughes GR
    Clin Rheum Dis; 1982 Apr; 8(1):279-98. PubMed ID: 6749400
    [No Abstract]   [Full Text] [Related]  

  • 10. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effectiveness of antimalarial drugs in rheumatic diseases.
    Aviña-Zubieta JA; Galindo-Rodriguez G; Newman S; Suarez-Almazor ME; Russell AS
    Ann Rheum Dis; 1998 Oct; 57(10):582-7. PubMed ID: 9893568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
    Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
    Tang C; Godfrey T; Stawell R; Nikpour M
    Intern Med J; 2012 Sep; 42(9):968-78. PubMed ID: 22827853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimalarial drug retinopathy: A typical « Bull's eyes » appearance of fundus.
    Guiot A; Couturier M; Tebib JG; Abouaf L; Coury F
    Joint Bone Spine; 2018 May; 85(3):369. PubMed ID: 28512007
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydroxychloroquine: a multifaceted treatment in lupus.
    Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
    Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.
    Bogaczewicz J; Sobów T; Bogaczewicz A; Robak E; Bienkowski P; Sysa-Jedrzejowska A; Wozniacka A
    Lupus; 2014 Feb; 23(2):188-93. PubMed ID: 24297641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimalarial drugs in pregnancy--the North American experience.
    Parke AL; Rothfield NF
    Lupus; 1996 Jun; 5 Suppl 1():S67-9. PubMed ID: 8803915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
    Parke A; West B
    J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of hydroxychloroquine in lupus pregnancy: the British experience.
    Khamashta MA; Buchanan NM; Hughes GR
    Lupus; 1996 Jun; 5 Suppl 1():S65-6. PubMed ID: 8803914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.